Checked
Class IIDrug recallOngoing
IMAAVY (nipocalimab-aahu) Injection recall
Recalled by J&J INNOVATIVE MEDICINE of Malvern, PA · FDA report 10/14/2026
Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.
- Class
- Class II
- Moderate
- Status
- Ongoing
- Recall started
- 09/23/2026
- Distribution
- See below
Reason for recall
Presence of particulate matter.
Class II: Use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
Recalled product
- Product
- IMAAVY (nipocalimab-aahu) Injection, 300 mg /1.62 mL (185 mg/mL) per single-dose vial, For Intravenous Infusion After Dilution, Rx only, Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044. NDC: 57894-800-01
- Lot and code info
- Lot JNYJ1208; Exp. 10/30/2027
- Quantity
- 49 vials
- Brand names
- IMAAVY
- Recall number
- D-0016-2027
- Event ID
- 99972
- Initiated by
- Voluntary: Firm initiated
Where it was distributed
OH
Recall timeline
- 09/23/2026Firm started the recall
- 10/08/2026FDA classified it as Class II
- 10/14/2026Published in the FDA enforcement report
Frequently asked questions
- Why was IMAAVY (nipocalimab-aahu) Injection recalled?
- Presence of particulate matter.
- What does Class II mean?
- Class II is FDA's moderate recall category: use of or exposure to the product may cause temporary or medically reversible health problems, or the chance of serious harm is remote.
- Is this recall still active?
- The FDA lists the recall as ongoing. The recall is still in progress.
Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 10/14/2026 · Do not rely on openFDA to make decisions regarding medical care